Aberrant expression of the DNA methyltransferases (DNMTs) and disruption of DNA methylation patterns are associated with carcinogenesis and cancer cell survival. The oncogenic MUC1-C protein is aberrantly overexpressed in diverse carcinomas; however, there is no known link between MUC1-C and DNA methylation. Our results demonstrate that MUC1-C induces the expression of DNMT1 and DNMT3b, but not DNMT3a, in breast and other carcinoma cell types. We show that MUC1-C occupies the DNMT1 and DNMT3b promoters in complexes with NF-κB p65 and drives DNMT1 and DNMT3b transcription. In this way, MUC1-C controls global DNA methylation as determined by analysis of LINE-1 repeat elements. The results further demonstrate that targeting MUC1-C downregulates DNA methylation of the CDH1 tumor suppressor gene in association with induction of E-cadherin expression. These findings provide compelling evidence that MUC1-C is of functional importance to induction of DNMT1 and DNMT3b and, in turn, changes in DNA methylation patterns in cancer cells.
INTRODUCTION
DNA methylation has an essential role in the epigenetic control of gene expression in cancer. [1] [2] [3] The DNA methyltransferases (DNMTs) are responsible for methylation of DNA through transfer of a methyl group to the cytosine base in CpG dinucleotides. 1 DNMT1 localizes to replication foci and is primarily responsible for maintaining DNA methylation patterns from template strands to newly synthesized DNA strands. 4 DNMT1 can function with DNMT3a and DNMT3b in de novo methyltransferase activity during development. 5, 6 Moreover, DNMT3a and DNMT3b establish de novo postreplicative DNA methylation patterns. 7, 8 DNMT1, DNMT3a and DNMT3b are often overexpressed in cancer cells. [9] [10] [11] Transcriptional induction of the DNMT1, DNMT3a and DNMT3b genes has been linked to activation of the RAS-JUN pathway 12, 13 and to binding of the Sp1 and Sp3 zinc-finger proteins to their promoters. 14, 15 In addition, DNMT1, DNMT3a and DNMT3b expression is repressed by (i) p53, Rb and FOXO3a, and (ii) diverse miRNAs. 16 Notably, DNMT1 and DNMT3b are both needed to silence genes in human cancer cells. 17, 18 However, signaling pathways that selectively and coordinately induce DNMT1 and DNMT3b are not known.
Mucin 1 (MUC1) is a heterodimeric protein that is aberrantly overexpressed by breast, lung and diverse other carcinomas. 19, 20 The oncogenic MUC1 C-terminal transmembrane subunit (MUC1-C) associates with receptor tyrosine kinases at the cell membrane and promotes their downstream signaling pathways. 19, 20 MUC1-C also localizes to the nucleus, in which it interacts with certain transcription factors and contributes to their transactivation function. 19, 20 In this manner, MUC1-C has been linked to the NF-κB pathway through interactions with TAK1 21 and the IKK complex. 22 MUC1-C also binds directly to NF-κB p65 and thereby contributes to the activation of NF-κB target genes, including MUC1 itself, in an autoinductive loop. 23 Involvement of MUC1-C in the TAK1 → IKK → NF-κB p65 pathway in cancer cells has further supported a direct role for MUC1-C in induction of (i) inflammatory cytokines, including IL-8, (ii) the epithelial-mesenchymal transition (EMT) with downregulation of the CDH1 gene that encodes E-cadherin (ECAD) and (iii) self-renewal capacity. [21] [22] [23] [24] [25] These findings have supported the notion that MUC1-C contributes to cancer progression by multiple mechanisms.
On the basis of premise that MUC1-C is of importance to the regulation of gene expression in cancer, the present studies investigated whether MUC1-C induces DNMT expression and alterations in DNA methylation patterns. The results demonstrate that MUC1-C selectively and coordinately activates the DNMT1 and DNMT3b genes in cancer cells and thereby global and genespecific changes in DNA methylation.
RESULTS AND DISCUSSION
Stable silencing of MUC1-C in BT-549 breast cancer cells was associated with suppression of DNMT1 mRNA and protein ( Figure 1a ). A similar response to MUC1-C silencing was observed in MDA-MB-231 breast cancer cells ( Figure 1b ), indicating that MUC1-C promotes DNMT1 expression. To confirm this notion, we overexpressed MUC1-C in MCF-7 breast cancer cells 24 and observed an increase in DNMT1 mRNA and protein (Figure 1c ), indicating that MUC1-C, and not the MUC1 N-terminal subunit (MUC1-N), is sufficient for this response. In extending these observations to other types of carcinomas, we found that silencing MUC1-C in KRAS mutant A549 (Supplementary Figure S1A ) and H460 (Supplementary Figure S1B ) non-small-cell lung cancer cells similarly results in decreased DNMT1 expression. In addition, MUC1-C conferred DNMT1 expression in SK-CO-1 colon cancer cells (Supplementary Figure S1C ), indicating that this association is found in diverse types of carcinomas. In further studies, we found that silencing MUC1-C in BT-549 cells suppressed DNMT3b, but not DNMT3a, expression ( Figure 1d ). The same pattern of response was observed in MDA-MB-231 ( Figure 1e ), A549 non-small-cell lung cancer (Supplementary Figure S2A ), H460 non-small-cell lung cancer cells (Supplementary Figure S2B ) and SK-CO-1 colon cancer cells (Supplementary Figure S2C ). We also found that overexpression of MUC1-C in MCF-7 cells increases DNMT3b and not DNMT3a (Figure 1f ). To provide additional support for these findings, we used other approaches for targeting MUC1-C expression. In this way, silencing MUC1 in H460 cells with clustered regularly interspaced short palindromic repeats/Cas9 editing resulted in the downregulation of DNMT1 and DNMT3b (Supplementary Figure S3A ). Moreover, targeting MUC1-C function in BT-549 and A549 cells with the GO-203 inhibitor 26 decreased DNMT1 and DNMT3b levels (Supplementary Figures  S3B and S3C ). These results demonstrate that MUC1-C selectively drives DNMT1 and DNMT3b, but not DNMT3a, expression in breast and other carcinoma cells.
On the basis of these findings, we searched the DNMT1 and DNMT3b promoters for the presence of cis-binding elements not shared with DNMT3a. Notably, an NF-κB binding site had been reported in the DNMT1 promoter ( Figure 2a ) 27 and putative consensus NF-κB sites were identified in the DNMT3b, but not in the DNMT3a, promoter ( Figure 2b) . Accordingly, and to investigate a transcriptional mechanism, we generated a DNMT1 promoter-luciferase reporter (Supplementary Figure S4A ) and showed that silencing MUC1-C in MDA-MB-231 (Figure 2a Figure S4D ). In addition, mutation of the putative NF-κB p65 binding sites in the DNMT1 promoter-luciferase reporter (Figure 2a , right) and DNMT3b promoter-luciferase reporter (Figure 2b , right) vectors decreased their activation. To extend this line of investigation, we found that silencing NF-κB p65 in BT-549 and MDA-MB-231 cells decreases DNMT1 and DNMT3b, but not DNMT3a, expression ( Figures 2c and d) . Similar results were obtained in A549 cells (Supplementary Figure S4E) . Moreover, treatment with the NF-κB inhibitor BAY11-7085 28 decreased expression of DNMT1 and DNMT3b, and not DNMT3a (Figure 2e ). MUC1-C constitutively activates the NF-κB p65 pathway in mesenchymal MDA-MB-231 and BT-549, but not in luminal MCF-7, cells. However, the enforced overexpression of MUC1-C in MCF-7 cells induces NF-κB p65 activity, 25 indicating that cell context is of importance for MUC1-C-induced activation of NF-κB p65 signaling. Indeed, in studies of MCF-7/MUC1-C cells, we also found that BAY11-7085 (i) attenuates activation of the DNMT1 promoter (Figure 2f , left), and (ii) suppresses DNMT1 and DNMT3b expression ( Figure 2f , right), providing further evidence that the MUC1-C → NF-κB p65 pathway [21] [22] [23] confers DNMT1 and DNMT3b activation.
MUC1-C binds directly to NF-κB p65 and promotes activation of NF-κB target genes, including MUC1 itself, in an autoinductive loop. 23 To investigate whether MUC1-C occupies the DNMT1 and DNMT3b promoters, we performed chromatin Supplementary Table S1 . The results (mean ± s.d. of three determinations) are expressed as relative mRNA levels compared with that obtained for cells expressing MUC1 shRNA (assigned a value of 1) (left and middle panels). Lysates were immunoblotted with the indicated antibodies (right panels). immunoprecipitation studies on MDA-MB-231 cells. Analysis of the DNMT1 promoter clearly demonstrated MUC1-C occupancy (Figure 3a , left) and the presence of NF-κB p65 (Figure 3a, right) . In addition, in re-chromatin immunoprecipitation, we found that NF-κB p65 occupies the DNMT1 promoter in a complex with MUC1-C (Figure 3b ), which is consistent with the above observation that DNMT1 activation is dependent on both MUC1-C and NF-κB p65. We also found that silencing MUC1-C decreases occupancy of NF-κB p65 on the DNMT1 promoter ( Figure 3c ). Similar results were obtained from studies of the DNMT3b promoter; that is, MUC1-C and NF-κB p65 occupancy (Figure 3d , left and right), and the detection of MUC1-C/NF-κB p65 complexes ( Figure 3e ). The results also demonstrate that MUC1-C promotes NF-κB p65 occupancy of the DNMT3b promoter ( Figure 3f ). The above findings invoked the possibility that MUC1-C also functions in regulating DNA methylation in cancer cells. Indeed, silencing MUC1-C in BT-549 ( Figure 4a ) and MDA-MB-231 (Supplementary Figure S5A ) cells was associated with significant decreases in the percentage of 5-methylcytosine in long interspersed nucleotide element-1 (LINE-1) repeats, a surrogate marker of global DNA methylation. [29] [30] [31] These effects of targeting MUC1-C were confirmed using bisulfite sequencing of LINE-1 repeats (Figure 4b ), further supporting a role for MUC1-C in inducing global DNA methylation. On the basis of these results Figure 2 . MUC1-C activates DNMT1 and DNMT3b expression by an NF-κB-mediated mechanism. (a) Schema of the DNMT1 promoterluciferase (pDNMT1-Luc) reporter with an NF-κB binding motif at − 833 to − 824 upstream to the transcription start site. MDA-MB-231 cells were transfected with (i) the empty pGL3-Basic Luc vector or pGL3-pDNMT1-Luc, and the SV-40-Renilla-Luc plasmid as an internal control (left), and the empty pGL3-Basic Luc vector, wild-type (WT) pGL3-pDNMT1-Luc or mutant pGL3-pDNMT1-Luc and the SV-40-Renilla-Luc plasmid (right). Dual luciferase activity was measured at 48 h after transfection. The results (mean ± s.d. of three determinations) are expressed as the relative luciferase activity compared with that obtained with (i) the MDA-MB-231/MUC1 shRNA cells (assigned a value of 1) (left) and (ii) the mutant pGL3-pDNMT1-Luc (assigned a value of 1) (right). (b) Schema of the DNMT3b promoter-luciferase (pDNMT3b-Luc) reporter with two putative consensus NF-κB binding sites at the indicated positions. MDA-MB-231 cells were transfected with the pGL3 vector, WT pGL3-pDNMT3b-Luc or mutant pGL3-pDNMT3b-Luc and SV-40-Renilla-Luc. The cells were then analyzed for luciferase activity as described above. and previous work demonstrating that MUC1-C promotes EMT and downregulation of ECAD expression, 24, 25 we investigated the involvement of MUC1-C in DNA methylation of the CDH1 promoter. Using immunoprecipitation of methylated DNA followed by qPCR of the precipitated DNA fragments, we found that silencing MUC1-C in MDA-MB-231 cells is associated with marked decreases in methylation of the CDH1 promoter (Supplementary Figure S5B) . In addition and in concert with this response, MUC1-C silencing resulted in significant induction of ECAD mRNA and protein (Supplementary Figure S5C) . Similarly, silencing MUC1-C in BT-549 cells was associated with decreased methylation of the CDH1 promoter and induction of ECAD expression (Figure 4c ). In addition, bisulfite conversion of genomic DNA and pyrosequencing of the CpG region of the CDH1 promoter (positions − 169 to − 116) demonstrated that MUC1-C silencing is associated with significant decreases in DNA methylation of multiple CpG sites (Figure 4d ).
Aberrant expression of DNMTs and changes in DNA methylation have been linked to cancer cell progression and survival. 2, 9, 11, 32, 33 Interestingly, genetic disruption of both DNMT1 and DNMT3b substantially reduces DNMT activity and DNA methylation, indicating that these DNMTs cooperate to silence genes in human cancer cells. 18 The present findings demonstrate that the MUC1-C oncoprotein is unique in that it selectively and coordinately induces DNMT1 and DNMT3b, but not DNMT3a, expression and thereby upregulates DNA methylation in diverse types of carcinoma cells (Figure 4e ). MUC1-C activates the TAK1 → IKK → NF-κB pathway in an autoinductive loop that includes a direct interaction with NF-κB p65 and the induction of MUC1 and other NF-κB target genes [19] [20] [21] [22] [23] (Figure 4e ). The present results thus provide support for a model in which MUC1-C → NF-κB p65 Supplementary Table S2 ) for the NF-κB p65 binding site in the DNMT1 promoter. The results (mean ± s.d. of three determinations) are expressed as the relative fold enrichment compared with that obtained for the IgG control (assigned a value of 1).
(d-f) The final DNA samples were amplified by qPCR with pairs of primers ( Supplementary Table S2 ) for the NF-κB p65 binding sites in the DNMT3b promoter. The results (mean ± s.d. of three determinations) are expressed as the relative fold enrichment compared with that obtained for the IgG control (assigned a value of 1). signaling links this inflammatory response to the induction of DNMTs (Figure 4e ). On the basis of these findings, we investigated the effects of targeting MUC1-C on DNA methylation patterns. LINE-1 retrotransposons constitute approximately 17 − 18% of the human genome and are aberrantly activated in cancer, and may contribute to genome instability. 34, 35 On the basis of the demonstration that MUC1-C regulates LINE-1 DNA methylation, experiments will be needed to assess whether MUC1-C has an effect on LINE-1 retrotransposon activity in cancer cells. In this regard and although global hypomethylation promotes LINE-1 activation in cancer cells, individual LINE-1 elements are activated only when hypomethylation occurs in the promoter region of that element. 36, 37 MUC1-C has been linked to the induction of EMT and the associated downregulation of ECAD expression in cancer cells. 24, 25 The present results extend the importance of MUC1-C in EMT by demonstrating that MUC1-C drives DNA methylation of the CDH1 promoter and, thereby, suppression of ECAD expression. These findings do not exclude the possibility that MUC1-C suppresses ECAD expression by additional mechanisms; for example, by promoting SNAIL-mediated repression of the CDH1 promoter. 38 The finding that targeting MUC1-C reverses EMT also raises the possibility that MUC1-C may epigenetically regulate other genes in the EMT program. 24, 25 In that line of reasoning, the MUC1 promoter itself is regulated by DNA methylation. [39] [40] [41] Accordingly, studies of interest will be to assess the effects of downregulating DNMT1 and/or DNMT3b on DNA methylation of the MUC1 promoter and MUC1-C expression. In summary, the present findings support the premise that targeting. MUC1-C could represent a therapeutic approach capable of influencing global and gene-specific epigenetic changes, and in turn the reprogramming of cancer cells.
ABBREVIATIONS DNMT, DNA methyltransferase; MUC1, mucin 1; EMT, epithelialmesenchymal transition; ECAD, E-cadherin; LINE-1, long interspersed nucleotide element-1.
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